Depression and anxiety in persons with Von Willebrand disease

Roberts, Jonathan C.; Kulkarni, Roshni; Kouides, Peter A.; Sidonio, Robert F.; Carpenter, Shannon L.; Konkle, Barbara A.; Wu, Joanne; Ullman, Megan M.; Curtis, Randall; Baker, Jean H.; Crook, Nicole; Nichol, Michael B.

doi:10.1111/hae.14725

Cited by 10 publications

(12 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anxiety and depression rates in our study were substantially less than those in a prospective study in individuals attending hemophilia treatment centers in the USA. 8 Overall rates of anxiety and depression in the US study were 58% and 64%, respectively, versus 8% and 11% among people diagnosed with VWD managed by GPs in this UK-based study. VWD complications associated with depression in the US study included self-reported chronic pain and joint problems, while joint problems were also associated with anxiety.…”

Section: Discussionmentioning

confidence: 62%

“…VWD complications associated with depression in the US study included self-reported chronic pain and joint problems, while joint problems were also associated with anxiety. 8 In addition, findings revealed that joint problems and not being in a relationship (ie, single, widowed, or divorced) were important predictors of depression and anxiety, while anxiety was also more common in adolescents (12–18 years of age) and individuals whose general health had deteriorated in the prior 3 months. 8 Although the study populations differed between the two studies, higher rates of anxiety and depression were observed in females diagnosed with VWD compared with males in both studies.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacologically Treated Anxiety and Depression in People Diagnosed with von Willebrand Disease: Matched Cohort Study

Hagberg¹,

Jick²,

Özen³

et al. 2023

JBM

View full text Add to dashboard Cite

Background People diagnosed with von Willebrand disease (VWD) have reduced quality of life versus the general population, and there is limited evidence of increased rates of anxiety and/or depression among people diagnosed with VWD. Aim To understand the association between VWD and mental health outcomes. Design and Setting A retrospective cohort study was conducted using the UK Clinical Practice Research Datalink (CPRD) GOLD database (1988–2016). Methods People diagnosed with VWD were matched 1:10 to randomly selected people in the database without VWD based on sex, birth year ±2 years, CPRD record start year ±2 years, and general practice attended. Individuals were followed from VWD diagnosis or match date to censoring (first event date, CPRD end date, or death). Treated anxiety and treated depression were identified by a diagnostic Read Code and a prescription for anxiety/depression medication recorded within 90 days of each other, after VWD diagnosis/match date. Results Treated anxiety was recorded in 89 of 1119 (8.0%) people diagnosed with VWD and 624 of 10,423 (6.0%) without VWD (age- and sex-adjusted incidence rate ratio [IRR], 1.37; 95% confidence interval [CI], 1.10–1.71). Treated depression was recorded in 119 of 1083 (11.0%) people diagnosed with VWD and 846 of 9845 (8.6%) without VWD (adjusted IRR, 1.35; 95% CI, 1.11–1.63). Females aged 20–39 and 0–19 years were at greatest risk for treated anxiety and treated depression, respectively. Conclusion Higher rates of treated anxiety and depression were observed among people diagnosed with versus without VWD, predominantly in young females.

show abstract

Section: Discussionmentioning

confidence: 62%

Section: Discussionmentioning

confidence: 99%

Pharmacologically Treated Anxiety and Depression in People Diagnosed with von Willebrand Disease: Matched Cohort Study

Hagberg¹,

Jick²,

Özen³

et al. 2023

JBM

View full text Add to dashboard Cite

show abstract

“…47 However, quality of life in VWD patients is known to be poor, especially for those with HMB, which is the most common presenting symptom. 48 This disconnect underscores the problem facing the VWD community-if current treatments are so effective, why is not quality of life better? In this paper, new and emerging therapies for VWD are summarized including rVWF, emicizumab, BT200, generalized haemostatic therapies, and nanotechnology-based therapies.…”

Section: New Treatment Options For Vwd: An Update 41 Introductionmentioning

confidence: 99%

“…There is a wealth of experience with currently existing treatments, including antifibrinolytics, desmopressin and pdVWF replacement which have been around for decades, and are widely considered safe and effective 47 . However, quality of life in VWD patients is known to be poor, especially for those with HMB, which is the most common presenting symptom 48 . This disconnect underscores the problem facing the VWD community—if current treatments are so effective, why is not quality of life better?…”

Section: Introductionmentioning

confidence: 99%

Diagnosis and treatment of von Willebrand disease in 2024 and beyond

James,

Leebeek,

Casari

et al. 2024

Haemophilia

View full text Add to dashboard Cite

Manuscript Background and AimThe diagnosis and clinical care of patients with von Willebrand disease (VWD) has continued to evolve since the characterization of the von Willebrand factor (VWF) gene in 1985. This condition is almost certainly the most common inherited bleeding disorder, and the major symptomatic burden of the disease is experienced by females during their reproductive years. Diagnosis relies on the identification of a personal and family history of excessive mucocutaneous bleeding, and laboratory features consistent with quantitative and/or qualitative abnormalities of VWF. This review focuses on three aspects of VWD management, with current updates and a look into the future.Manuscript ThemesFirst, we will address the role of genetics in the diagnosis and possible therapies for VWD. With current technologies, VWD genetic diagnosis is usually confined to the confirmation of type 2 subtypes of the disease and type 3 VWD analysis for family planning. While type 3 VWD is a potential candidate for the application of gene therapy, no treatments are currently close to entering the clinic. Second, the peri‐procedural management of patients with VWD remains an important element of care. The choice of product, its dose and schedule all require careful consideration depending upon the type and disruptive nature of the planned procedure. Lastly, in addition to gene therapy, several other novel therapeutic interventions are also being developed for bleeding and prophylaxis in VWD. These include a VWF aptamer interfering with VWF clearance and bioengineered forms of VWF.

show abstract

“… 7 However, quality of life in patients with VWD is known to be poor, especially for those with HMB, which is the most common presenting symptom. 8 , 9 , 10 , 11 This disconnect underscores the problem facing the VWD community: if current treatments are good, why are patients still suffering?…”

Section: Introductionmentioning

confidence: 99%

New and emerging therapies for women, girls, and people with the potential to menstruate with VWD

Casari,

Leung,

James

2023

Blood Advances

View full text Add to dashboard Cite

Innovation in therapies for von Willebrand disease (VWD) patients has lagged far behind hemophilia, creating inequity in the bleeding disorder community. Although currently existing treatments of antifibrinolytics, desmopressin and plasma-derived von Willebrand factor (pdVWF) replacement are considered effective, multiple studies report poor quality of life in VWD patients, especially those with heavy menstrual bleeding (HMB). This disconnect underscores the need for novel therapies that are safe and effective and that consider a patient's specific contraceptive and reproductive needs. Recombinant VWF (rVWF) is the most recent new therapy for VWD; the data specific to women is reviewed. We also present emerging data on emicizumab for the treatment of VWD, BT200 (rondoraptivon pegol), generalized hemostatic therapies (VGA039 and HMB-011) as well as treatments based on nanotechnology (platelet-inspired nanoparticles and KB-V13A12). We are optimistic as we move towards pivotal clinical trials for these elegant and innovative treatments.

show abstract

Depression and anxiety in persons with Von Willebrand disease

Cited by 10 publications

References 31 publications

Pharmacologically Treated Anxiety and Depression in People Diagnosed with von Willebrand Disease: Matched Cohort Study

Pharmacologically Treated Anxiety and Depression in People Diagnosed with von Willebrand Disease: Matched Cohort Study

Diagnosis and treatment of von Willebrand disease in 2024 and beyond

New and emerging therapies for women, girls, and people with the potential to menstruate with VWD

Contact Info

Product

Resources

About